Kdo hydrolase is required for francisella tularensis virulence and evasion of TLR2-mediated innate immunity

mBio

Volumn 4, Issue 1, 2013, Pages

  Okan, Nihal A ^a   Chalabaev, Sabina ^a   Kim, Tae Hyun ^a   Fink, Avner ^a   Ross, Robin A ^a   Kasper, Dennis L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; INTERLEUKIN 1BETA; PROTEIN KDHAB; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSIDASE; TLR2 PROTEIN, MOUSE; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FRANCISELLA TULARENSIS; IMMUNOPATHOGENESIS; IN VITRO STUDY; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; LUNG LAVAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TULAREMIA; VACCINATION; ANIMAL; CHEMISTRY; DISEASE MODEL; ENZYMOLOGY; GENE DELETION; GENETICS; IMMUNE EVASION; IMMUNOLOGY; LD 50; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; PATHOGENICITY; PATHOLOGY; SURVIVAL;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; FRANCISELLA TULARENSIS; GENE DELETION; GLYCOSIDE HYDROLASES; IMMUNE EVASION; LETHAL DOSE 50; MACROPHAGES; MICE; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 2; TULAREMIA; VIRULENCE FACTORS;

MLCS; MLOWN;

EID: 84874600754     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00638-12     Document Type: Article

References (55)

1. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. 2007. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol. 178:4538-4547.
2. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, Kawula TH. 2008. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect. Immun. 76:5843-5852.
3. Malik M, Bakshi CS, Sahay B, Shah A, Lotz SA, Sellati TJ. 2006. Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect. Immun. 74:3657-3662.
4. Mares CA, Ojeda SS, Morris EG, Li Q, Teale JM. 2008. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Infect. Immun. 76: 3001-3010.
5. Moreland JG, Hook JS, Bailey G, Ulland T, Nauseef WM. 2009. Francisella tularensis directly interacts with the endothelium and recruits neutrophils with a blunted inflammatory phenotype. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:L1076-L1084.
6. Cowley SC. 2009. Proinflammatory cytokines in pneumonic tularemia: too much too late? J. Leukoc. Biol. 86:469-470.
7. Woolard MD, Frelinger JA. 2008. Outsmarting the host: bacteria modulating the immune response. Immunol. Res. 41:188-202.
8. Kanistanon D, Hajjar AM, Pelletier MR, Gallagher LA, Kalhorn T, Shaffer SA, Goodlett DR, Rohmer L, Brittnacher MJ, Skerrett SJ, Ernst RK. 2008. A Francisella mutant in lipid A carbohydrate modification elicits protective immunity. PLoS Pathog. 4:e24. http://dx.doi.org/10.1371 /journal.ppat.0040024.
9. Sandström G, Sjöstedt A, Johansson T, Kuoppa K, Williams JC. 1992. Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS. FEMS Microbiol. Immunol. 5:201-210.
10. Wang X, Ribeiro AA, Guan Z, Abraham SN, Raetz CR. 2007. Attenuated virulence of a Francisella mutant lacking the lipid A 4=-phosphatase. Proc. Natl. Acad. Sci. U. S. A. 104:4136-4141.
11. Wang X, Ribeiro AA, Guan Z, McGrath SC, Cotter RJ, Raetz CR. 2006. Structure and biosynthesis of free lipid A molecules that replace lipopolysaccharide in Francisella tularensis subsp. novicida. Biochemistry 45: 14427-14440.
12. Galanos C, Lüderitz O, Rietschel ET, Westphal O, Brade H, Brade L, Freudenberg M, Schade U, Imoto M, Yoshimura H, Kusumpyo S, Shiba T. 1985. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 148:1-5.
13. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71:635-700.
14. Chalabaev S, Kim TH, Ross R, Derian A, Kasper DL. 2010. 3-Deoxy-D-manno-octulosonic acid (Kdo) hydrolase identified in Francisella tularensis, Helicobacter pylori, and Legionella pneumophila. J. Biol. Chem. 285: 34330-34336.
15. Zhao J, Raetz CR. 2010. A two-component Kdo hydrolase in the inner membrane of Francisella novicida. Mol. Microbiol. 78:820-836.
16. Wang X, Karbarz MJ, McGrath SC, Cotter RJ, Raetz CR. 2004. MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of Francisella novicida LpxE expressed in Escherichia coli. J. Biol. Chem. 279:49470-49478.
17. Stead C, Tran A, Ferguson D, Jr, McGrath S, Cotter R, Trent S. 2005. A novel 3-deoxy-D-manno-octulosonic acid (Kdo) hydrolase that removes the outer Kdo sugar of Helicobacter pylori lipopolysaccharide. J. Bacteriol. 187:3374-3383.
18. Stead CM, Zhao J, Raetz CR, Trent MS. 2010. Removal of the outer Kdo from Helicobacter pylori lipopolysaccharide and its impact on the bacterial surface. Mol. Microbiol. 78:837-852.
19. Raynaud C, Meibom KL, Lety MA, Dubail I, Candela T, Frapy E, Charbit A. 2007. Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect. Immun. 75: 536-541.
20. Katz J, Zhang P, Martin M, Vogel SN, Michalek SM. 2006. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect. Immun. 74:2809-2816.
21. Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ. 2009. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine 27:388-395.
22. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240.
23. Wu MF, Yang CY, Lin TL, Wang JT, Yang FL, Wu SH, Hu BS, Chou TY, Tsai MD, Lin CH, Hsieh SL. 2009. Humoral immunity against capsule polysaccharide protects the host from magA+ Klebsiella pneumoniae-induced lethal disease by evading Toll-like receptor 4 signaling. Infect. Immun. 77:615-621.
24. Zarrella TM, Singh A, Bitsaktsis C, Rahman T, Sahay B, Feustel PJ, Gosselin EJ, Sellati TJ, Hazlett KR. 2011. Host-adaptation of Francisella tularensis alters the bacterium's surface-carbohydrates to hinder effectors of innate and adaptive immunity. PLoS One 6:e22335. http://dx.doi.org /10.1371/journal.pone.0022335.
25. Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y, Gearhart PJ, Chesko KL, Viscardi RM, Vogel SN. 2011. Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J. Leukoc. Biol. 90:787-797.
26. Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL. 2012. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine. J. Infect. Dis. 205:1056-1065.
27. Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW. 2008. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol. Rev. 225:244-255.
28. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. 2007. In vivo negative selection screen identifies genes required for Francisella virulence. Proc. Natl. Acad. Sci. U. S. A. 104:6037-6042.
29. Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, Comstock LE, Conlan JW, Rubin EJ, Tzianabos AO, Kasper DL. 2007. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect. Immun. 75:2591-2602.
30. Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, Stead CM, Trent MS, Miller SI. 2006. The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway. J. Bacteriol. 188:191-201.
31. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. 2002. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun. 70:4092-4098.
32. Kawasaki K, Ernst RK, Miller SI. 2004. 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4. J. Biol. Chem. 279: 20044-20048.
33. Pyles RB, Jezek GE, Eaves-Pyles TD. 2010. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun. 78:1700-1710.
34. Rozak DA, Gelhaus HC, Smith M, Zadeh M, Huzella L, Waag D, Adamovicz JJ. 2010. CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J. Immune Based Ther. Vaccines 8:2.
35. West TE, Pelletier MR, Majure MC, Lembo A, Hajjar AM, Skerrett SJ. 2008. Inhalation of Francisella novicida delta mglA causes replicative infection that elicits innate and adaptive responses but is not protective against invasive pneumonic tularemia. Microbes Infect. 10:773-780.
36. Gaekwad J, Zhang Y, Zhang W, Reeves J, Wolfert MA, Boons GJ. 2010. Differential induction of innate immune responses by synthetic lipid A derivatives. J. Biol. Chem. 285:29375-29386.
37. Muroi M, Tanamoto K. 2002. The polysaccharide portion plays an indispensable role in Salmonella lipopolysaccharide-induced activation of NFkappaB through human Toll-like receptor 4. Infect. Immun. 70: 6043-6047.
38. Zughaier SM, Tzeng YL, Zimmer SM, Datta A, Carlson RW, Stephens DS. 2004. Neisseria meningitidis lipooligosaccharide structuredependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect. Immun. 72:371-380.
39. Brandenburg K, Andrä J, Müller M, Koch MH, Garidel P. 2003. Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr. Res. 338:2477-2489.
40. de Cock H, Brandenburg K, Wiese A, Holst O, Seydel U. 1999. Nonlamellar structure and negative charges of lipopolysaccharides required for efficient folding of outer membrane protein PhoE of Escherichia coli. J. Biol. Chem. 274:5114-5119.
41. Kramer RA, Brandenburg K, Vandeputte-Rutten L, Werkhoven M, Gros P, Dekker N, Egmond MR. 2002. Lipopolysaccharide regions involved in the activation of Escherichia coli outer membrane protease OmpT. Eur. J. Biochem. 269:1746-1752.
42. Snyder S, Kim D, McIntosh TJ. 1999. Lipopolysaccharide bilayer structure: effect of chemotype, core mutations, divalent cations, and temperature. Biochemistry 38:10758-10767.
43. Thakran S, Li H, Lavine CL, Miller MA, Bina JE, Bina XR, Re F. 2008. Identification of Francisella tularensis lipoproteins that stimulate the Tolllike receptor (TLR) 2/TLR1 heterodimer. J. Biol. Chem. 283:3751-3760.
44. Conlan JW. 2011. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol. 6:391-405.
45. Ireland PM, Lebutt H, Thomas RM, Oyston PC. 2011. A Francisella tularensis SCHU S4 mutant deficient in gamma-glutamyl transferase activity induces protective immunity: characterisation of an attenuated vaccine candidate. Microbiology 157:3172-3179.
46. Qin A, Scott DW, Thompson JA, Mann BJ. 2009. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect. Immun. 77:152-161.
47. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academy Press, Washington, DC.
48. Lauriano CM, Barker JR, Nano FE, Arulanandam BP, Klose KE. 2003. Allelic exchange in Francisella tularensis using PCR products. FEMS Microbiol. Lett. 229:195-202.
49. Kim TH, Sebastian S, Pinkham JT, Ross RA, Blalock LT, Kasper DL. 2010. Characterization of the O-antigen polymerase (Wzy) of Francisella tularensis. J. Biol. Chem. 285:27839-27849.
50. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
51. Westphal O, Jann K. 1965. Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5:83-91.
52. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. 2004. Guideline to reference gene selection for quantitative real-time PCR. B+7iochem. Biophys. Res. Commun. 313:856-862.
53. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T) method. Methods 25:402-408.
54. Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. 2009. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin. Vaccine Immunol. 16:414-422.
55. Vinogradov E, Perry MB, Conlan JW. 2002. Structural analysis of Francisella tularensis lipopolysaccharide. Eur. J. Biochem. 269:6112-6118.